| FDA-approved medicine (2)Approved for the specific uses on its label, which may not be this goal. |
|---|
| Tesamorelin | HIV-associated abdominal-fat trial (2007) · Human randomized trial Visceral fat decreased 15.2% with tesamorelin and increased 5.0% with placebo. Some lipid measures also improved. IGF-I increased by 81.0% versus a 5.0% decrease with placebo. More tesamorelin recipients withdrew because of adverse events, despite no significant overall adverse-event difference. Limitation: Visceral-fat change is not the same as total body-weight loss. The trial population and HIV-associated condition are central; long-term cardiovascular benefit was not established by this endpoint. Studied: 412 people with HIV and abdominal fat accumulation; 86% were men. | FDA-approved | FDA label |
|---|
| Vosoritide | Vosoritide in children with achondroplasia (2020) · Human randomized phase 3 trial Adjusted annualized growth velocity was 1.57 cm/year higher with vosoritide, with a 95% CI of 1.22–1.93 cm/year. Limitation: This report did not establish final adult height or long-term functional outcomes. It does not apply to healthy adults with closed growth plates. Studied: 121 children aged five to under 18 years with achondroplasia. | FDA-approved | FDA label |
|---|
| Randomized human trials (4)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition. |
|---|
| ACE-031 | ACE-031 in boys with Duchenne muscular dystrophy (stopped early) (2017) · Human randomized phase 2 trial ACE-031 was not linked to serious or severe adverse events, but the study was stopped after the second dose level because of nosebleeds and telangiectasias (small dilated blood vessels). Treated boys showed a trend toward keeping their 6-minute walking distance while the placebo group declined, which was not statistically significant, and trends toward more lean mass and bone density and less fat mass. Limitation: A small safety trial that was stopped early, so the muscle and walking findings are trends, not proof of benefit. Several authors worked for the developer. The side effects that ended the trial were not related to muscle, and the results say nothing in favor of using ACE-031 for muscle building in healthy people. Studied: Boys with Duchenne muscular dystrophy who could still walk. | Not approved | Trials only |
|---|
| Ghrelin | Ghrelin infusion and food intake (2001) · Human randomized crossover study Energy intake was approximately 28% higher after ghrelin, and appetite ratings increased. The tested gastric-emptying measure did not change. Limitation: An acute study in nine healthy people does not establish a chronic disease benefit, sustained weight change, or effects in cachexia. Studied: Nine healthy volunteers. | Not approved | Trials only |
|---|
| Ipamorelin | Postoperative ileus proof-of-concept trial (2014) · Human randomized trial Median time to tolerating a standardized meal was 25.3 hours with ipamorelin and 32.6 hours with placebo (p=0.15). Key and secondary efficacy analyses did not show significant between-group differences. Limitation: Small proof-of-concept study with varied underlying conditions. This setting, route, and endpoint do not test muscle gain, fat loss, sleep improvement, or long-term use. Studied: 117 patients enrolled after bowel resection; 114 in the safety and modified intention-to-treat populations. | Not approved | Trials only |
|---|
| MK-677 | Ibutamoren in healthy older adults (2008) · Human randomized trial Fat-free mass increased with ibutamoren versus placebo, but strength and function did not improve. Fasting glucose increased and insulin sensitivity decreased. Limitation: More fat-free mass does not establish stronger muscles, improved independence, or a longevity benefit. Studied: 65 healthy adults aged 60–81. | Not approved | Trials only |
|---|
| Small or uncontrolled human studies (7)Human reports without randomization, such as pilots, case series or open-label studies. |
|---|
| CJC-1295 | Long-acting CJC-1295 (2006) · Human pharmacology trials Mean growth hormone rose two- to tenfold for at least six days; IGF-1 rose 1.5- to threefold for nine to eleven days after a single exposure. The estimated half-life was 5.8–8.1 days. Limitation: The endpoints were hormone concentrations. These were studies of long-acting CJC-1295, not proof of muscle gain or equivalence to products labeled “CJC no DAC.” Studied: Healthy adults aged 21–61. | Not approved | Very limited |
|---|
| Follistatin 344 | Follistatin-344 listings · eye-harm signal (2020) · Human retrospective case series Central serous chorioretinopathy was identified. Fluid resolved after an average 2.3 months in eight single-exposure cases; three multiple-exposure cases had recurrence. Limitation: Referral selection, lack of a denominator, possible confounding, and uncertain product identity prevent estimating incidence or proving causation. It supplies no evidence of muscle-building efficacy. Studied: 11 male bodybuilding athletes seen at one clinic with reduced vision after injections labeled follistatin-344. | Not approved | None |
|---|
| GHRP-2 | Appetite and hormone experiment (2005) · Small human physiology study Participants ate approximately 36% more during GHRP-2 exposure, and growth-hormone release increased. Every participant ate more in the active condition. Limitation: An acute meal response in seven men is not evidence for sustained body-composition improvement. Increased appetite may be relevant when interpreting weight-loss marketing. Studied: Seven lean healthy men. | Not approved | Very limited |
|---|
| GHRP-6 | Sleep and hormone experiment (1995) · Human physiology experiment Growth hormone, ACTH, and cortisol increased. Stage-2 sleep increased; slow-wave sleep did not. Limitation: The response was not restricted to growth hormone. An overnight physiology study does not establish treatment for chronic insomnia, injury recovery, or long-term athletic performance. Studied: Healthy male volunteers. | Not approved | Very limited |
|---|
| Hexarelin | Early healthy-volunteer physiology study (1994) · Human physiology study Growth hormone rose after hexarelin, peaked at roughly 30 minutes, and returned toward baseline by about 240 minutes. Limitation: The study did not establish changes in strength, body composition, injury recovery, or long-term clinical outcomes. Twelve volunteers and an acute observation window cannot resolve sustained benefit or safety. Studied: 12 healthy adult men. | Not approved | Very limited |
|---|
| PEG-MGF | Natural MGF after exercise · young vs older men (2003) · Human observational study MGF messenger RNA rose significantly in the young men but not in the older men. Limitation: Measures the body's own gene activity, not the effect of taking a synthetic peptide. Small groups. Studied: 8 young men (25–36) and 7 older men (70–82). | Not approved | None |
|---|
| Sermorelin | Geref pediatric growth study (1996) · Human open-label study Average height velocity increased from 4.1 cm/year at baseline to 7.2 cm/year at 12 months. Limitation: There was no blinded placebo comparison. Growth in hormone-deficient children cannot establish anti-aging, body-composition, or performance benefits in adults. Studied: 110 previously untreated children with growth-hormone deficiency; 86 eligible for efficacy analysis. | Withdrawn | Very limited |
|---|
| Animal and lab studies only (4)No human study in our sources. |
|---|
| IGF-1 DES | See the profile for the animal and lab research. | Not approved | None |
|---|
| IGF-1 LR3 | See the profile for the animal and lab research. | Not approved | None |
|---|
| MGF | See the profile for the animal and lab research. | Not approved | None |
|---|
| Modified GRF 1-29 | See the profile for the animal and lab research. | Not approved | None |
|---|